Loading clinical trials...
Loading clinical trials...
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Conditions
Interventions
Reproxalap Ophthalmic Solution (0.25%)
Reproxalap Ophthalmic Solution (0.1%)
+1 more
Locations
6
United States
The Eye Care Group
Waterbury, Connecticut, United States
Midwest Cornea Associates
Indianapolis, Indiana, United States
Central Maine Eye Care
Lewiston, Maine, United States
Andover Eye Associates
Andover, Massachusetts, United States
Andover Eye Associates
Raynham, Massachusetts, United States
Total Eye Care
Memphis, Tennessee, United States
Start Date
January 2, 2018
Primary Completion Date
July 11, 2018
Completion Date
July 11, 2018
Last Updated
February 6, 2025
NCT07295691
NCT03135327
NCT06771427
NCT06220474
NCT06291194
NCT04685109
Lead Sponsor
Aldeyra Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions